CEBPA and rhabdomyolysis: 1. Hematologic: Peripheral blood MRD (ddPCR, q2 months for 1 year)2. Safety: Creatine kinase (q4 weeks, monitor for rhabdomyolysis)3. Pharmacodynamics: H3K4me1/H3K27ac levels (ChIP-seq, end of cycle 1; target: restoration of CEBPA/PU.1 chromatin occupancy)